SE420566B - DIAGNOSTIZER FOR INTRAVASCULAR ADMINISTRATION - Google Patents

DIAGNOSTIZER FOR INTRAVASCULAR ADMINISTRATION

Info

Publication number
SE420566B
SE420566B SE7407461A SE7407461A SE420566B SE 420566 B SE420566 B SE 420566B SE 7407461 A SE7407461 A SE 7407461A SE 7407461 A SE7407461 A SE 7407461A SE 420566 B SE420566 B SE 420566B
Authority
SE
Sweden
Prior art keywords
june
blood plasma
water
intravascularly
intravascular administration
Prior art date
Application number
SE7407461A
Other languages
Swedish (sv)
Other versions
SE7407461L (en
Inventor
U S E Rothman
B J Lindberg
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE7407461A priority Critical patent/SE420566B/en
Priority to AU81646/75A priority patent/AU8164675A/en
Priority to DE19752524278 priority patent/DE2524278A1/en
Priority to CA228,779A priority patent/CA1039274A/en
Priority to GB24287/75A priority patent/GB1518813A/en
Priority to FR7517632A priority patent/FR2273516A1/en
Priority to NL7506743A priority patent/NL7506743A/en
Priority to JP50067731A priority patent/JPS517113A/ja
Publication of SE7407461L publication Critical patent/SE7407461L/en
Publication of SE420566B publication Critical patent/SE420566B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/003—Crosslinking of starch
    • C08B31/006—Crosslinking of derivatives of starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

1518813 Diagnostic agents PHARMACIA AB 5 June 1975 [6 June 1974] 24287/75 Heading A5B [Also in Divisions C3 and G1] A diagnostic agent for intravascular administration and subsequent analysis in vivo or in vitro consists of a radioactive component, e.g. Tc<SP>99m</SP> (e.g. sodium pertechnetate) which is bound to, and/or enclosed in and/or exists in admixture with particles of a water-insoluble but hydrophilic, swellable, three dimensional network of molecules of a polyglucose polymer or physiologically acceptable derivative thereof which is cross linked covalently, the network being degradable by 2-amylase in blood plasma into water-soluble fragments either directly or subsequent to a preliminary splitting-off of substituents which may be present in the polysaccharide through the action of an enzyme in blood plasma (see Division C3). The compositions may be administered intravascularly whereafter the radioactive radiation is measured over the relevant body portion or on a sample taken from the body (e.g. an intravascularly taken sample).
SE7407461A 1974-06-06 1974-06-06 DIAGNOSTIZER FOR INTRAVASCULAR ADMINISTRATION SE420566B (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE7407461A SE420566B (en) 1974-06-06 1974-06-06 DIAGNOSTIZER FOR INTRAVASCULAR ADMINISTRATION
AU81646/75A AU8164675A (en) 1974-06-06 1975-05-29 A diagnostic agent
DE19752524278 DE2524278A1 (en) 1974-06-06 1975-05-31 DIAGNOSTIC MEANS, AIDS FOR PRODUCTION AND DIAGNOSIS METHODS
CA228,779A CA1039274A (en) 1974-06-06 1975-06-05 Diagnostic agent
GB24287/75A GB1518813A (en) 1974-06-06 1975-06-05 Diagnostic agent
FR7517632A FR2273516A1 (en) 1974-06-06 1975-06-05 DIAGNOSIS AGENT FOR INTRAVASCULAR ADMINISTRATION
NL7506743A NL7506743A (en) 1974-06-06 1975-06-06 DIAGNOSTIC.
JP50067731A JPS517113A (en) 1974-06-06 1975-06-06

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7407461A SE420566B (en) 1974-06-06 1974-06-06 DIAGNOSTIZER FOR INTRAVASCULAR ADMINISTRATION

Publications (2)

Publication Number Publication Date
SE7407461L SE7407461L (en) 1975-12-08
SE420566B true SE420566B (en) 1981-10-19

Family

ID=20321348

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7407461A SE420566B (en) 1974-06-06 1974-06-06 DIAGNOSTIZER FOR INTRAVASCULAR ADMINISTRATION

Country Status (8)

Country Link
JP (1) JPS517113A (en)
AU (1) AU8164675A (en)
CA (1) CA1039274A (en)
DE (1) DE2524278A1 (en)
FR (1) FR2273516A1 (en)
GB (1) GB1518813A (en)
NL (1) NL7506743A (en)
SE (1) SE420566B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002772A1 (en) * 1983-12-21 1985-07-04 Schroeder Ulf Diagnostic and contrast agent

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0093757A1 (en) * 1981-11-12 1983-11-16 Ulf SCHRÖDER Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
FR2548902B1 (en) * 1983-07-13 1986-04-11 Guerbet Sa THERAPEUTIC EMBOLIZATION GEL

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002772A1 (en) * 1983-12-21 1985-07-04 Schroeder Ulf Diagnostic and contrast agent

Also Published As

Publication number Publication date
DE2524278A1 (en) 1975-12-18
CA1039274A (en) 1978-09-26
SE7407461L (en) 1975-12-08
FR2273516A1 (en) 1976-01-02
FR2273516B1 (en) 1979-01-05
GB1518813A (en) 1978-07-26
AU8164675A (en) 1976-12-02
JPS517113A (en) 1976-01-21
NL7506743A (en) 1975-12-09

Similar Documents

Publication Publication Date Title
EP0787017B2 (en) Diagnostic preparation for detection of helicobacter pylori
CA1165686A (en) Radioactive diagnostic agent and non-radioactive carrier therefor
JPS60155138A (en) Manufacture of heparin or heparinoid with improved intestinal absorption and medicine thereof
US4071613A (en) Stabilized alcohol solution of reducing salt formulations for use in preparing radioisotope labeled scanning agents: liver scanning technetium-99m colloid and method of preparation
NL7506743A (en) DIAGNOSTIC.
Whitby Enzymic formation of a new riboflavin derivative
Schilsky et al. Biliary copper excretion capacity in intact animals: correlation between ATP7B function, hepatic mass, and biliary copper excretion
Ekenved ABSORPTION FROM DIFFERENT TYPES OF IRON TABLETS‐CORRELATION BETWEEN SERUM IRON INCREASE AND TOTAL ABSORPTION OF IRON
EP0063946A1 (en) Diagnosis of kidney function
DE69001000T2 (en) RADIOACTIVE DIAGNOSTIC.
Esquerre et al. Kinetics of technetium-labeled heparin in thromboembolism: Preliminary Report
Ainsworth An ultrastructural method for the use of polyvinylpyrrolidone and dextrans as electron opaque tracers.
EP0280135A2 (en) Protein C-inhibitor (PCI) as a pharmaceutical and diagnostic agent, process for the preparation of such a pharmaceutical or diagnostic agent and a composition containing PCI
Caputo et al. Letterer-Siwe disease in an octogenarian
Balaban et al. Effect of the radiolabel mediator tropolone on lymphocyte structure and function
Hudson et al. Tumour uptake of thallium-201 chloride
Turan et al. Evaluation of 99m Tc-citrate, 67 Gacitrate and 99m Tc (V) dimercaptosuccinic acid for the scintigraphic visualization of acute appendicitis
Rosenau Dangers in the use of certain halogenated phthaleins as functional tests
JPS5842846B2 (en) Technetium-99m labeled radiological diagnostic agent for liver and bone marrow scanning and its manufacturing method
JPS63170400A (en) Radioactive medicine and high polymer compound for preparation thereof
GB2055044A (en) Glucuronidase activity and/or phdependent pharmaceuticals and their methods of production and use for selective treatment of diseases
Duchon Tyrosine metabolism in melanoma
JPS60126231A (en) Radioactie diagnostic agent
Perin et al. Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: Effects of methylprednisolone, dexamethasone, indomethacin and methotrexate
Chatterjee Debnath et al. Technetium-99m cysteine; a novel radiopharmaceutical for detection of experimental myocardial infarction in rats